Ajax-Loading

Johnson & Johnson - End Period Cash Flow

Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "End-Period-Cash-Flow" stands at 99.39 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Johnson & Johnson's third quarter result of 18.23 Billion USD for the item "End Period Cash Flow" represents a decrease of -1.86 percent compared to it's second quarter result.

Also, Johnson & Johnson's third quarter result of 18.23 Billion USD for the item "End Period Cash Flow" represents a decrease of -8.75 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 99.39 Billion USD for the item "End Period Cash Flow" represents a decrease of -1.73 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 7.81 percent compared to the value the year prior.
The 1 year change in percent is 7.81.
The 3 year change in percent is 110.17.
The 5 year change in percent is 57.82.
The 10 year change in percent is 95.69.

The Serie's long term average value is 68.92 Billion United States Dollars. It's latest available value, on 09/30/2025, is 44.21 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2022, to it's latest available value, on 09/30/2025, is +111.79%.
The Serie's change in percent from it's maximum value, on 03/31/2025, to it's latest available value, on 09/30/2025, is -7.49%.

End Period Cash Flow for Related Companies:

LogoNameMarket Cap (USD)
LogoEli Lilly and Company - End Period Cash Flow905,699,262,464.00
LogoAbbVie Inc - End Period Cash Flow399,570,305,024.00
LogoRoche Holding AG - End Period Cash Flow317,433,206,677.55
LogoAstraZeneca PLC - End Period Cash Flow280,205,508,085.11
LogoNovartis AG - End Period Cash Flow255,096,620,580.91